Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Patients receiving hemodialysis and peritoneal dialysis differ in diet (severe restrictions on fruits and vegetables in patients on hemodialysis), quality of life (higher in patients on peritoneal dialysis) and outcomes. Uremic toxins levels in patients with end-stage CKD depends on endogenous production by intestinal microbiota and diet. High serum levels of gut-derived uremic toxins, especially p-cresyl sulfate (pCS), indoxyl sulfate (IS), trimethylamine-N-oxide (TMAO) and hippurate have been associated with adverse outcomes in patients with chronic kidney disease.The aim of this study was to investigate the blood metabolic profile in patients on hemodialysis and peritoneal dialysis and the effect of the treatment with “Maxilac”, the synbiotic drug on the blood metabolic profile.
In our study we included 34 hemodialysis patients (1gr), age 58,7±16.4 years (18 f/16 m), and 40 (2gr) patients, age 55±16.4 years (22 f/18 m) on peritoneal dialysis at our nephrology center. The study of metabolites included 2 stages before taking “Maxilac” and after 2 months. Blood samples were analyzed using 1H-nuclear magnetic resonance spectroscopy focusing on low-molecular-weight metabolites. We used standard statistical methods and oPLS-DA analyses employing the MetaboAnalyst 6.0 platform. A total of 55 metabolites were identified in serum samples patients with CKD on PD and hemodialysis.
Initially, Student's t-test demonstrated a statistically significant difference in the levels of metabolites in the study groups: the levels of pCS (301,4±43,1 vs 371,6±57,0 µmol/l), IS (55,9±28,0 vs 73,1±37,5 µmol/l), TMAO (991,81±461,1 vs 1258,4±649,6 µmol/l) and hippurate (138,0±71,0 vs 383,5±183,1 µmol/l) were higher in the group of patients on hemodialysis, while creatinine levels in these groups did not differ significantly. Statistically significant changes in metabolite levels were detected in the study groups after treatment with Maxilac (p ≤0,05). In patients undergoing hemodialysis, the level of metabolites changed: threonine, hippurate, xanthosine, aspartate, acetone, proline, myoinositol, inosine, 1-methylhistidine, carnitine, lactate, 2-oxoisocaproate, dimethylamine, 3-methyl-2-oxovalerate (Fig. 1). PD patients showed changed levels of sarcosine, fumarate, methionine, ornithine, acetylcholine, isobutyrate, inosine, hypoxanthine and phenylalanine (Fig. 2).
The data obtained indicates that in patients on PD, the level of uremic toxins was lower than in patients on HD. Therapy with the drug "Maxilac" causes specific metabolic changes in patients on HD and PD, Therapy with the drug "Maxilac" causes specific metabolic changes in patients on HD and PD, affecting the metabolism of amino acids, lipids and glucose.
